| Identification | Back Directory | [Name]
[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylamino]methanesulphonic acid | [CAS]
50567-35-6 | [Synonyms]
[(2,3-Dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylamino]methanesulfonic acid [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylamino]methanesulphonic acid Methanesulfonic acid, 1-[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylamino]- | [EINECS(EC#)]
256-627-7 | [Molecular Formula]
C13H17N3O4S | [MDL Number]
MFCD00046078 | [MOL File]
50567-35-6.mol | [Molecular Weight]
311.36 |
| Hazard Information | Back Directory | [Uses]
Metamizol (Methamizole) is an anti-thyroid agent, which blocks thyroid hormone production from the thyroid gland. Metamizol can cause hepatotoxicity[1]. | [Definition]
ChEBI: A pyrazole that is antiipyrine substituted at C-4 by a methyl(sulfomethyl)amino group, the sodium salt of which, metamizole sodium, was widely used as a powerful analgesic and antipyretic, but withdrawn from many markets from the 1970s due to a risk of cau
ing risk of causing agranulocytosis. | [in vivo]
Metamizo (Methamizole; 100 mg/kg; i.p.; once; male Swiss albino mice) causes hepatotoxicity as revealed by an increase in serum alanine aminotransferase (ALT) activity[1]. Metamizo (100 mg/kg; i.p.; once; male Swiss albino mice) causes a decrease in hepatic glutathione (GSH) contents[1].
| Animal Model: | Male Swiss albino mice (6 weeks old, 25-40 g)[1] | | Dosage: | 100 mg/kg | | Administration: | Intraperitoneal injection; once | | Result: | Increased serum ALT level at 5 hours and the maximum serum ALT levels occurred at 5 hours. |
| Animal Model: | Male Swiss albino mice (6 weeks old, 25-40 g)[1] | | Dosage: | 100 mg/kg | | Administration: | Intraperitoneal injection; once | | Result: | Induced reduction in hepatic glutathione (GSH) content in mice. |
| [References]
[1] Heidari R, et, al. Effects of Enzyme Induction and/or Glutathione Depletion on Methimazole-Induced Hepatotoxicity in Mice and the Protective Role of N-Acetylcysteine. Adv Pharm Bull. 2014;4(1):21-8. DOI:10.5681/apb.2014.004 |
|
|